Retroscreen Virology Group PLC Investor Event (5310I)
02 Juin 2014 - 8:00AM
UK Regulatory
TIDMRVG
RNS Number : 5310I
Retroscreen Virology Group PLC
02 June 2014
For immediate release 07.00: 2 June 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
INVESTOR EVENT
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce that it
will host an investor event on Wednesday 4 June 2014.
The event will open at 16.30 GMT in the auditorium at the Queen
Mary BioEnterprises Innovation Centre (42 New Road, London, E1
2AX). The meeting will be hosted by Kym Denny, Chief Executive of
Retroscreen, and will include presentations from the Company's
hVIVO research team. The presentations will commence at 17.00 and
will conclude at 18.30.
The event is intended to provide further insight into
Retroscreen's innovation strategy. No material new information on
current trading or future financial performance will be disclosed
in these presentations.
As capacity is limited, please contact James Black at Numis to
register your interest in the event.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness better because the
Company believes that the best way to understand human disease is
by studying it in humans, not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFLDEAIIVIS
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024